The prognostic significance of p53, p27kip1, p21waf1, HER-2/neu, and ki67 proteins expression in gastric cancer:: A clinicopathological and lmmunohistochemical study of 121 Arab patients

被引:56
作者
Al-Moundhri, MS
Nirmala, V
Al-Hadabi, I
Al-Mawaly, K
Burney, I
Al-Nabhani, M
Thomas, V
Ganguly, SS
Grant, C
机构
[1] Sultan Qaboos Univ, Dept Med, Coll Med, Med Oncol Unit, Muscat, Oman
[2] Sultan Qaboos Univ, Coll Med, Dept Pathol, Muscat, Oman
[3] Sultan Qaboos Univ, Coll Med, Dept Epidemiol & Med Stat, Muscat, Oman
[4] Sultan Qaboos Univ, Coll Med, Dept Surg, Muscat, Oman
关键词
gastric cancer; stomach; prognosis; p53; p27(kip1); p21; HER-2/neu; Ki67; antigen; immunohistochemistry; Arabs;
D O I
10.1002/jso.20324
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The variability of prognosis within a pathological stage of gastric cancer (GC) at presentation, underscores the need for specific biological markers to identify subgroups of patients with aggressive course for intensive treatment. To our knowledge, this is the first study from an Arab population reporting on the relationship of p53, p27(kip1), p21(waf1), HER-2/neu, and Ki67 expression, and clinicopathological features and their prognostic significance. Methods: Formalin-fixed paraffin-embedded tumors were studied by immunohistochemistry, using monoclonal antibodies to p53, p27(kip1), p21(waf1), HER-2/neu, and Ki67. The results were correlated with clinicopathological features and survival. Results: M:F = 80:41; median age = 60 years; stage III and IV = 71%; and median follow-up = 34.4 months. Positive expression rates of p53, p27(kip1), p21(waf1), Ki67, and HER-2/neu were 54%, 40%, 8.3%, 70%, and 12% respectively. p53 expression correlated with age < 60 years (P = 0.03), tumor size > 5cm (P = 0.01), p27(kip1), and Ki67 expression (P = 0.0001), and HER-2/neu (P = 0.04). p21(waf1) correlated inversely with T-stage (P = 0.008) and Her-2/nett expression correlated with histological grade (P=0.04) and T-stage (P=0.008). Univariate analysis showed that p53 overexpression (P = 0.01), fungating and infiltrative macroscopic appearance (P = 0.02), size > 5 cm (P = 0.0001), lymph node metastasis (P = 0.0001), p T3 and T4 disease (P = 0.01), and overall stage III and IV (P = 0.0001) disease were adverse prognostic factors. Patients with tumor profiles p53 (-)/p27 (+) had better survival than those with p53 (+)/p27(kip1) (-)(P=0.02). On multivariate analysis by Cox regression model, the expression of p53 (P = 0.03) and lymph node involvement (P = 0.01) were significant adverse prognostic factors for overall survival. Conclusions: The expression of p53 in Arab patients with GC correlates with aggressive tumor characteristics and is an independent prognostic factor. The combined analysis of p53 and p27(kip1) is of added prognostic value.
引用
收藏
页码:243 / 252
页数:10
相关论文
共 72 条
  • [51] 2-Q
  • [52] Combined evaluation of expressions of p53 and p21 proteins as prognostic factors for patients with gastric carcinoma
    Okuyama, T
    Maehara, Y
    Kabashima, A
    Takahashi, I
    Kakeji, Y
    Sugimachi, K
    [J]. ONCOLOGY, 2002, 63 (04) : 353 - 361
  • [53] Clinicopathological significance and survival influence of p53 protein expression in gastric carcinoma
    Pinto-de-Sousa, J
    Silva, F
    David, L
    Leitao, D
    Seixas, M
    Pimenta, A
    Cardoso-de-Oliveira, M
    [J]. HISTOPATHOLOGY, 2004, 44 (04) : 323 - 331
  • [54] c-erb B-2 expression is associated with tumor location and venous invasion and influences survival of patients with gastric carcinoma
    Pinto-de-Sousa, J
    David, L
    Almeida, R
    Leitao, D
    Preto, JR
    Seixas, M
    Pimenta, A
    [J]. INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY, 2002, 10 (04) : 247 - 256
  • [55] P27(KIP1), A CYCLIN-CDK INHIBITOR, LINKS TRANSFORMING GROWTH-FACTOR-BETA AND CONTACT INHIBITION TO CELL-CYCLE ARREST
    POLYAK, K
    KATO, JY
    SOLOMON, MJ
    SHERR, CJ
    MASSAGUE, J
    ROBERTS, JM
    KOFF, A
    [J]. GENES & DEVELOPMENT, 1994, 8 (01) : 9 - 22
  • [56] RANZANI GN, 1995, CANCER EPIDEM BIOMAR, V4, P223
  • [57] Current status and future perspectives in gastric cancer management
    Roukos, DH
    [J]. CANCER TREATMENT REVIEWS, 2000, 26 (04) : 243 - 255
  • [58] Sanz-Ortega J, 2000, HISTOL HISTOPATHOL, V15, P455, DOI 10.14670/HH-15.455
  • [59] Saragoni L, 2003, Pathologica, V95, P22
  • [60] Sgambato A, 2000, CANCER-AM CANCER SOC, V89, P2247, DOI 10.1002/1097-0142(20001201)89:11<2247::AID-CNCR13>3.0.CO